Results 111 to 120 of about 1,716,393 (201)

Antiviral Development for the Polio Endgame: Current Progress and Future Directions

Pathogens
As the world is approaching the eradication of wild poliovirus serotype 1, the last of the three wild types, the question of how to maintain a polio-free world becomes imminent.
Hang Xie, Eric E. Rhoden, Hong-Mei Liu, Folake Ogunsemowo, Bernardo A. Mainou, Rachel M. Burke, Cara C. Burns   +6 more
doaj   +1 more source

Randomized Controlled Clinical Trial of Bivalent Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine in Nigerian Children. [PDF]

J Infect Dis, 2022
Tagbo BN, Verma H, Mahmud ZM, Ernest K, Nnani RO, Chukwubike C, Craig KT, Hamisu A, Weldon WC, Oberste SM, Jeyaseelan V, Braka F, Mkanda P, Esangbedo D, Olowu A, Nwaze E, Sutter RW.   +16 more
europepmc   +1 more source

Quantitative RT-PCR Assays for Quantification of Undesirable Mutants in the Novel Type 2 Oral Poliovirus Vaccine. [PDF]

Vaccines (Basel), 2022
Manukyan H, Wahid R, Ansari A, Tritama E, Macadam A, Konz J, Chumakov K, Laassri M.   +7 more
europepmc   +1 more source

Assessment of open data kit mobile technology adoption to enhance reporting of supportive supervision conducted for oral poliovirus vaccine supplementary immunization activities in Nigeria, March 2017-February 2020. [PDF]

Pan Afr Med J, 2023
Bammeke P, Erbeto T, Aregay A, Kamran Z, Adamu US, Damisa E, Usifoh N, Nsubuga P, Waziri N, Bolu O, Dagoe E, Shuaib F.   +11 more
europepmc   +1 more source

Immune persistence after different polio sequential immunization schedules in Chinese infants

npj Vaccines
Trivalent oral poliovirus vaccine (tOPV) has been withdrawn and instead an inactivated poliovirus vaccine (IPV) and bivalent type 1 and type 3 OPV (bOPV) sequential immunization schedule has been implemented since 2016, but no immune persistence data are
Ting Zhao, Jing Li, Teng Huang, Zhi-Fang Ying, Yan-Chun Che, Zhi-Mei Zhao, Yu-Ting Fu, Jun-Hui Tao, Qing-Hai Yang, Ding-Kai Wei, Guo-Liang Li, Li Yi, Yu-Ping Zhao, Hong-Bo Chen, Jian-Feng Wang, Rui-Ju Jiang, Lei Yu, Wei Cai, Wei Yang, Ming-Xue Xie, Qiong-Zhou Yin, Jing Pu, Li Shi, Chao Hong, Yan Deng, Lu-Kui Cai, Jian Zhou, Yu Wen, Hong-Sen Li, Wei Huang, Zhao-Jun Mo, Chang-Gui Li, Qi-Han Li, Jing-Si Yang   +33 more
doaj   +1 more source

The molecular determinants and consequences of recombination in the evolution of human enteroviruses [PDF]

Recombination is an important biological process in a diverse range of viruses, particularly those with single-stranded ribonucleic acid (RNA) genomes including the enteroviruses.
Lowry, Kym
core  

Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response. [PDF]

Vaccine, 2023
Kalkowska DA, Pallansch MA, Wassilak SGF, Cochi SL, Thompson KM.   +4 more
europepmc   +1 more source

Effect of Mycobacterium vaccae (SRL172) immunotherapy on radiographic healing in tuberculosis. [PDF]

, 2004
OBJECTIVE: Controlled trials have failed to show an effect of Mycobacterium vaccae immunotherapy on treatment outcome and mortality in patients with tuberculosis (TB); however, several studies have suggested improvement in radiographic clearing and ...
Mugerwa, RD, Onyebujoh, P, Ormerod, LP, Johnson, JL, Zumla, A, Nunn, AJ, Mwinga, A, Fourie, PB, Chintu, C, Ngwira, B   +9 more
core  

A Health Economic Analysis for Oral Poliovirus Vaccine to Prevent COVID-19 in the United States. [PDF]

Risk Anal, 2021
Thompson KM, Kalkowska DA, Badizadegan K.   +2 more
europepmc   +1 more source

Immuno-persistence of the different primary polio vaccine schedules and immunogenicity of the booster dose by sabin inactivated or bivalent oral poliovirus vaccine in children aged 4 years: an open-label, randomised, controlled phase 4 trial in China. [PDF]

Lancet Reg Health West Pac, 2023
Tang X, Xiao Y, Deng X, Zhou Y, Chen H, Yan R, Zhu Y, Wang S, Wang H, Zhu X, Luo L, Liu Y, Yin Z, Zhang G, Chen Z, Jiang J, Yang X, He H.   +17 more
europepmc   +1 more source